Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.
Thirteen premenopausal women who each received 400 micrograms three times daily of intranasal buserelin for 6 months as treatment for endometriosis participated in this study. Cortical bone mineral content (BMC) in the mid-shaft of the right femur measured by dual photon densitometry, and trabecular bone density (TBD) in the lumbar vertebrae (L2-4) measured by quantitative computed tomography, were evaluated prior to, at the end of 6 months' buserelin treatment and after 6 months off treatment. Significant hypo-oestrogenism (P less than 0.001) was sustained during the period on treatment. The significant reduction in the mean lumbar vertebral TBD of 5.9% (P less than 0.02) observed at the end of treatment with buserelin was regained within 6 months following resumption of ovarian activity. There was a marginally significant (P = 0.07) reduction of only 0.9% in the mean femoral cortical BMC at the end of treatment. Six months after the end of treatment cortical BMC values were not significantly different from the pretreatment values. There was no significant correlation between the degree of hypo-oestrogenism and the corresponding change in vertebral TBD, (r = 0.20; P less than 0.10).
Matta
W H
WH
Academic Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK.
Shaw
R W
RW
Hesp
R
R
Evans
R
R
D000328:Adult; D001842:Bone and Bones / Q000187:drug effects*; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005269:Femur / Q000032:analysis; D006801:Humans; D008159:Lumbar Vertebrae / Q000032:analysis; D008593:Menopause; D008903:Minerals / Q000032:analysis; D010053:Ovary / Q000502:physiology
D008903:Minerals; D002064:Buserelin